B6-huMSLN Mouse
제품명
B6-huMSLN Mouse
제품 ID
C001856
품종 계통
C57BL/6NCya-Mslntm1(hMSLN)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “B6-huMSLN Mouse (카탈로그 번호 C001856)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자명
유전자 별칭
MPF, SMRP
NCBI ID
염색체
Chr 16
MGI ID
Datasheet
품종 계통 설명
The MSLN gene encodes a preproprotein that is proteolytically processed into two distinct proteins: megakaryocyte potentiating factor (MPF) and mesothelin [1]. MPF functions as a cytokine that promotes the formation of megakaryocytes in bone marrow, while mesothelin is a glycosylphosphatidylinositol-anchored cell-surface protein that may play a role in cell adhesion. While mesothelin expression is normally low and restricted to mesothelial cells lining the pleura, peritoneum, and pericardium, it is highly overexpressed in several epithelial cancers, including malignant mesothelioma, ovarian cancer, pancreatic cancer, and certain types of lung cancer [2-3]. This high expression and its function in promoting cell proliferation and metastasis make mesothelin a significant biomarker and a target for cancer therapies [4].
The B6-huMSLN mouse model was generated by replacing sequences from the ATG start codon to the TGA stop codon of the endogenous mouse Msln gene with the sequences from the ATG start codon to the TGA stop codon of the human MSLN gene. This model can be used to study the pathological mechanisms and therapeutic approaches for several cancers, including malignant mesothelioma, ovarian cancer, pancreatic cancer, and certain types of lung cancer, as well as for the development of MSLN-targeted drugs.
Reference
Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008 Jan;44(1):46-53.
Hagerty BL, Takabe K. Biology of Mesothelin and Clinical Implications: A Review of Existing Literature. World J Oncol. 2023 Oct;14(5):340-349.
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, Irving M, Coukos G, Lanitis E, Dunn SM. Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. J Immunother Cancer. 2025 Mar 13;13(3):e010063.
Kumari S. Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy. Cancers (Basel). 2025 Mar 26;17(7):1118.
변형 전략
The sequences from the ATG start codon to the TGA stop codon of the endogenous mouse Msln gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human MSLN gene.
Figure 1. Gene editing strategy of B6-huMSLN mice.
응용 분야
MSLN-targeted drug screening, development, and evaluation;
Research on pathological mechanisms and therapeutic approaches for several cancers.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.